# Qilu Pharmaceutical Co., Ltd. clinical trials: 200 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 200 trials with Qilu Pharmaceutical Co., Ltd. as lead sponsor, 98 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Qilu Pharmaceutical Co., Ltd.: 200 rows for $10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 200
- Recruiting or not yet: 98
- Read on: November 19, 2026

## Trials

The 25 newest of 200, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933432 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933432) |
| November 12, 2026 | NCT07933419 | Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Other Advanced Solid Tumors | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933419) |
| November 10, 2026 | NCT07927556 | A Phase II Clinical Trial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension Who Are... | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Uncontrolled Hypertension | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927556) |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| October 26, 2026 | NCT07894211 | QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Extrapulmonary Neuroendocrine Carcinoma | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894211) |
| October 6, 2026 | NCT07861139 | Comparative Study of QL1209 and Perjeta® in Healthy Male Participants | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861139) |
| September 21, 2026 | NCT07829588 | Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | RAS Wild-type Metastatic Colorectal Cancer | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829588) |
| September 3, 2026 | NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih... | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Extensive-stage Small Cell Lung Cancer | 556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802821) |
| August 7, 2026 | NCT07751315 | A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751315) |
| July 29, 2026 | NCT07735104 | The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Cancer Cachexia, Cancer Cachexia Syndrome | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735104) |
| July 28, 2026 | NCT07730632 | Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730632) |
| July 24, 2026 | NCT07724756 | Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724756) |
| July 21, 2026 | NCT07716449 | QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Gastric or Gastroesophageal Junction Adenocarcinoma | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716449) |
| June 9, 2026 | NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Prostate Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636707) |
| June 8, 2026 | NCT07632690 | QLC5508 in Participants With Metastatic Prostate Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Prostate Cancer | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632690) |
| June 2, 2026 | NCT07620366 | To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Metabolic Dysfunction-associated Steatohepatitis (MASH) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620366) |
| June 2, 2026 | NCT07620041 | Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Refractory or Relapsed Solid Tumors | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620041) |
| May 13, 2026 | NCT07585565 | A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With... | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Parkinson's Disease | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585565) |
| May 1, 2026 | NCT07560449 | QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Malignant Plasma Cell Neoplasms | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560449) |
| April 24, 2026 | NCT07550465 | Study of QLS1410 in the Treatment of Primary Aldosteronism. | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Primary Aldosteronism | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550465) |
| April 6, 2026 | NCT07511647 | A Phase 3 Clinical Study of QL2106 Injection | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Plaque Psoriasis | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511647) |
| March 24, 2026 | NCT07489612 | QLS1410 in Participants With Uncontrolled Hypertension | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Enrolling by invitation | Hypertension (HTN) | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489612) |
| March 24, 2026 | NCT07489599 | A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's... | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI) | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489599) |
| March 24, 2026 | NCT07489586 | A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489586) |
| March 23, 2026 | NCT07487103 | Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Type 2 Diabetes | 478 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487103) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 70 |
| Phase 1/2 | 19 |
| Phase 2 | 33 |
| Phase 2/3 | 8 |
| Phase 3 | 62 |
| Phase 4 | 2 |
| Not applicable | 4 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 64 |
| Not yet recruiting | 62 |
| Recruiting | 36 |
| Completed | 31 |
| Active not recruiting | 5 |
| Enrolling by invitation | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Multiple Myeloma | 8 |
| Recurrence | 7 |
| Breast Neoplasms | 6 |
| Neoplasms | 5 |
| Colorectal Neoplasms | 5 |
| Prostatic Neoplasms | 5 |
| Dermatitis, Atopic | 5 |
| Hepatitis B, Chronic | 4 |
| Small Cell Lung Carcinoma | 4 |
| Uterine Cervical Neoplasms | 4 |
| Ovarian Neoplasms | 3 |
| Lung Neoplasms | 3 |
| COVID-19 | 3 |
| Hyperlipoproteinemia Type II | 3 |
| Pancreatic Neoplasms | 3 |
| Diabetes Mellitus, Type 2 | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Schizophrenia | 2 |
| Hematologic Neoplasms | 2 |
| Stomach Neoplasms | 2 |
| Colonic Neoplasms | 2 |
| Febrile Neutropenia | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Alzheimer Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Leather products manufacturers in the United States](https://specstream.ai/data/businesses/leather-products-manufacturers/united-states)
- [Freight and cargo companies in the United States](https://specstream.ai/data/businesses/freight-and-cargo-companies/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [B2B outdoor advertising companies in the United States](https://specstream.ai/data/businesses/b2b-outdoor-advertising-companies/united-states)
